GO:0014829 vascular associated smooth muscle contraction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014829 (vascular associated smooth muscle contraction) is a biological process in which actin/myosin complex activity generates force through ATP hydrolysis, changing smooth muscle geometry and always coupled to chemo-mechanical energy conversion.
• The process is driven by Ca2+-calmodulin-dependent activation of myosin light chain kinase (MLCK), phosphorylation of the 20-kDa myosin regulatory light chain (MLC20), and actomyosin cross-bridge cycling.
• RhoA/Rho-kinase (ROCK) signaling enhances contraction by inhibiting myosin light chain phosphatase (MLCP) and increasing Ca2+ sensitivity, a mechanism implicated in vascular disease [3,5].
• Cytoskeletal adaptor proteins such as paxillin and Crk-associated substrate (CAS) modulate contraction through Rho-kinase activation and actin remodeling [5,8].
• Dysregulated vascular smooth muscle contraction contributes to hypertension, vasospasm, sickle cell disease vasculopathy, and age-related vascular dysfunction [2,4,7].
• Computational and experimental models of vascular smooth muscle contraction reveal instability and nonlinearity, highlighting the need for robust experimental validation.
Description
Vascular associated smooth muscle contraction (GO:0014829) is the biological process by which smooth muscle cells in blood vessels generate force and shorten, thereby regulating vascular tone, blood flow, and blood pressure. This process is fundamental to cardiovascular homeostasis and is tightly coupled to chemo-mechanical energy conversion, where ATP hydrolysis by the actin/myosin complex drives a change in smooth muscle geometry. Understanding the molecular players and regulatory networks of vascular smooth muscle contraction is essential for deciphering the pathophysiology of hypertension, vasospasm, and other vascular disorders [2,3]. Recent studies have highlighted the importance of epigenetic and RNA modification pathways, such as YY1-mediated m6A regulation, in controlling vascular resistance and blood pressure dynamics. Moreover, computational models of vascular smooth muscle cell contraction have revealed inherent instabilities, underscoring the complexity of the system and the need for integrated experimental and theoretical approaches. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of GO:0014829, covering its definition, mechanism, key genes, disease relevance, and state-of-the-art research methods including CRISPR-based models.
vascular associated smooth muscle contraction At A Glance
| GO ID | GO:0014829 |
|---|---|
| GO term | vascular associated smooth muscle contraction |
| Ontology | biological_process |
| Synonym | vascular smooth muscle contraction |
| Major function | Generation of force and shortening of vascular smooth muscle cells via actin/myosin ATP hydrolysis, regulating vascular tone and blood flow |
| Cellular location | Vascular tissue (smooth muscle cells of blood vessel walls) |
| Energy coupling | Always coupled to chemo-mechanical energy conversion (ATP hydrolysis) |
| Key molecular players | Myosin light chain kinase (MLCK), myosin regulatory light chain (MLC20), RhoA/Rho-kinase, myosin light chain phosphatase (MLCP), actin, calmodulin |
| Related processes | Calcium signaling, Rho-kinase signaling, actin cytoskeleton reorganization, vascular tone regulation |
What Is GO:0014829?
According to the Gene Ontology, vascular associated smooth muscle contraction (GO:0014829) is a biological process occurring in vascular tissue whereby actin/myosin complex activity generates force through ATP hydrolysis, resulting in a change in smooth muscle geometry. This process is always coupled to chemo-mechanical energy conversion. In simpler terms, it is the ATP-powered shortening of smooth muscle cells in blood vessel walls that regulates vessel diameter and blood pressure.
Why Is vascular associated smooth muscle contraction Important in Cell Biology?
Vascular associated smooth muscle contraction is central to the regulation of blood pressure, tissue perfusion, and cardiovascular homeostasis. Dysregulation of this process is a hallmark of major human diseases including hypertension, vasospasm, sickle cell disease-associated vasculopathy, and age-related vascular dysfunction [2,4,7]. The process is also a key target for antihypertensive and vasodilator therapies, and understanding its molecular mechanisms can reveal novel therapeutic targets. Furthermore, the interplay between contractile machinery and epigenetic regulators such as YY1 highlights the complexity of vascular resistance control and offers new avenues for intervention.
• Regulates vascular tone and blood pressure, making it a therapeutic target for hypertension [2,3].
• Dysregulated contraction contributes to vasospasm and ischemic disorders.
• Sickle erythrocyte constituents enhance vascular smooth muscle contraction, linking to sickle cell disease vasculopathy.
• Aging alters vascular smooth muscle and endothelial functions, affecting contraction.
• Rho-kinase-mediated Ca2+ sensitization is a key mechanism in abnormal vascular contraction.
• Cytoskeletal adaptor proteins like CAS and paxillin modulate contractile signaling [5,8].
• Computational models of contraction reveal instability, guiding experimental design.
• Epigenetic regulation via YY1 and m6A RNA modifications controls vascular resistance.
• Sphingosylphosphorylcholine (SPC) induces abnormal contraction via endocytosis-dependent uptake.
• Understanding contraction mechanisms aids in developing targeted therapies for vascular diseases.
What Happens During vascular associated smooth muscle contraction?
Calcium-dependent activation of myosin light chain kinase (MLCK)
In simple terms: Calcium enters the cell and activates an enzyme that switches on the contraction machinery.
An increase in intracellular Ca2+ binds to calmodulin, forming a Ca2+-calmodulin complex that activates myosin light chain kinase (MLCK). MLCK then phosphorylates the 20-kDa myosin regulatory light chain (MLC20) at Ser19, initiating actomyosin cross-bridge cycling and force generation. This Ca2+-dependent pathway is the primary trigger for vascular smooth muscle contraction.
Actomyosin cross-bridge cycling and force generation
In simple terms: The molecular motors pull on actin filaments, causing the muscle cell to shorten.
Phosphorylated MLC20 activates myosin ATPase, which hydrolyzes ATP to drive conformational changes in the myosin head, enabling it to bind actin and generate force through cross-bridge cycling. This chemo-mechanical energy conversion results in smooth muscle shortening and changes in vascular geometry. The process is highly dynamic and can be modulated by load and other factors.
RhoA/Rho-kinase-mediated Ca2+ sensitization
In simple terms: A separate signaling pathway makes the muscle more sensitive to calcium, enhancing contraction.
The small GTPase RhoA activates Rho-kinase (ROCK), which inhibits myosin light chain phosphatase (MLCP) by phosphorylating its myosin-binding subunit. This inhibition prevents dephosphorylation of MLC20, leading to increased contraction at a given Ca2+ concentration, a phenomenon known as Ca2+ sensitization [3,5]. Rho-kinase also regulates actin cytoskeleton dynamics and interacts with adaptor proteins such as paxillin to promote abnormal contraction.
Cytoskeletal remodeling and adaptor protein signaling
In simple terms: Scaffolding proteins help organize the contraction machinery and its regulation.
Adaptor proteins such as Crk-associated substrate (CAS) and paxillin play critical roles in vascular smooth muscle contraction by linking signaling pathways to the actin cytoskeleton. CAS is involved in the regulation of contraction through its interaction with Crk and other proteins. Paxillin participates in sphingosylphosphorylcholine (SPC)-induced abnormal contraction by regulating Rho-kinase activation. These proteins help integrate mechanical and biochemical signals to fine-tune contractile responses.
Energy metabolism and chemo-mechanical coupling
In simple terms: The contraction process uses ATP as its energy source and is tightly linked to energy conversion.
ATP hydrolysis by the actin/myosin complex is the fundamental energy source for vascular smooth muscle contraction. This process is always coupled to chemo-mechanical energy conversion, meaning that the chemical energy from ATP is directly converted into mechanical work. The efficiency and stability of this coupling can be studied using computational models, which have revealed potential instabilities in the system.
Key Genes Involved in GO:0014829 vascular associated smooth muscle contraction
The following genes and proteins are key players in vascular associated smooth muscle contraction, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYLK | Encodes myosin light chain kinase (MLCK), which phosphorylates MLC20 to initiate contraction | Central regulator of Ca2+-dependent contraction; target for modulating vascular tone |
| MYL9 | Encodes the 20-kDa myosin regulatory light chain (MLC20), the substrate of MLCK | Phosphorylation status determines contractile activity; biomarker of contraction |
| RHOA | Small GTPase that activates Rho-kinase to promote Ca2+ sensitization | Key mediator of abnormal contraction in vascular disease [3,5] |
| ROCK1 | Rho-kinase isoform that inhibits MLCP and enhances contraction | Therapeutic target for vasospasm and hypertension [3,5] |
| ROCK2 | Rho-kinase isoform involved in Ca2+ sensitization and cytoskeletal remodeling | Modulates vascular smooth muscle contractility |
| PPP1R12A | Encodes the myosin-binding subunit of myosin light chain phosphatase (MLCP) | Phosphorylation by Rho-kinase inhibits MLCP, increasing contraction |
| CALM1 | Calmodulin, calcium sensor that activates MLCK | Essential for Ca2+-dependent contraction |
| ACTA2 | Smooth muscle alpha-actin, a component of the contractile apparatus | Structural and functional role in force generation |
| CAS (BCAR1) | Crk-associated substrate, adaptor protein regulating contraction | Modulates actin cytoskeleton and contractile signaling |
| PXN | Paxillin, focal adhesion protein involved in Rho-kinase activation | Participates in SPC-induced abnormal contraction |
| YY1 | Transcription factor regulating m6A RNA modifications in vascular smooth muscle cells | Controls vascular resistance and blood pressure dynamics |
| SPC (SPHK1) | Sphingosylphosphorylcholine, a lipid mediator that induces contraction | Taken up via endocytosis to trigger abnormal contraction |
| MYH11 | Smooth muscle myosin heavy chain, the motor protein | Essential for force generation; mutations linked to vascular disorders |
| CNN1 | Calponin, actin-binding protein that modulates contraction | Regulates contractility and cytoskeletal dynamics |
| LMOD1 | Leiomodin 1, actin filament nucleator | Involved in smooth muscle contractile apparatus |
| TAGLN | Transgelin, actin-binding protein | Modulates actin cytoskeleton and contraction |
| MYOCD | Myocardin, transcriptional coactivator of smooth muscle genes | Master regulator of smooth muscle differentiation and contractility |
| SRF | Serum response factor, transcription factor cooperating with myocardin | Regulates expression of contractile genes |
How Is vascular associated smooth muscle contraction Regulated?
Vascular associated smooth muscle contraction is regulated at multiple levels. Acute regulation involves Ca2+/calmodulin-dependent activation of MLCK and RhoA/Rho-kinase-mediated inhibition of MLCP, which together determine the phosphorylation state of MLC20 and the strength of contraction. Epigenetic regulation has emerged as a critical layer: the transcription factor YY1 controls m6A RNA modifications in vascular smooth muscle cells, thereby regulating vascular resistance and blood pressure dynamics. Additionally, lipid mediators such as sphingosylphosphorylcholine (SPC) can induce abnormal contraction through endocytosis-dependent uptake and activation of Rho-kinase [5,6]. Cytoskeletal adaptor proteins like CAS and paxillin further modulate contractile signaling by linking to actin dynamics and Rho-kinase [5,8]. Computational models suggest that the system exhibits inherent instabilities, which may be relevant to pathological states.
vascular associated smooth muscle contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| YY1 | Hypertension, vascular resistance | Smooth muscle-specific YY1 knockout or overexpression in mice |
| RHOA | Vasospasm, hypertension | Conditional RhoA knockout or point mutation (G14V) in vascular smooth muscle |
| ROCK1/ROCK2 | Vasospasm, hypertension | Kinase-dead knock-in or pharmacological inhibition [3,5] |
| PXN | SPC-induced abnormal contraction | Paxillin knockout or phospho-mutant knock-in in smooth muscle cells |
| BCAR1 (CAS) | Vascular contraction regulation | CAS knockout mice or smooth muscle-specific deletion |
Hypertension and Vascular Resistance
Enhanced vascular smooth muscle contraction is a major contributor to increased peripheral resistance in hypertension. YY1-mediated epigenetic control of m6A RNA modifications regulates vascular resistance and blood pressure dynamics, identifying YY1 as a potential therapeutic target. RhoA/Rho-kinase-mediated Ca2+ sensitization is also implicated in hypertensive vascular remodeling.
Sickle Cell Disease Vasculopathy
Sickle erythrocyte constituents enhance vascular smooth muscle contraction, contributing to the vasculopathy observed in sickle cell disease. This effect involves multiple mechanisms that increase contractile tone and may lead to vaso-occlusive crises.
Age-Related Vascular Dysfunction
Aging alters both vascular smooth muscle and endothelial functions, leading to impaired regulation of vascular tone. These changes can result in increased contraction and reduced vasodilation, contributing to age-related cardiovascular diseases.
Vasospasm and Abnormal Contraction
Sphingosylphosphorylcholine (SPC) induces abnormal vascular smooth muscle contraction via endocytosis-dependent uptake and activation of Rho-kinase, with paxillin playing a key role. This mechanism is relevant to vasospastic disorders such as cerebral vasospasm after subarachnoid hemorrhage [5,6].
From vascular associated smooth muscle contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate vascular smooth muscle contraction? | Smooth muscle-specific knockout (e.g., Cre-lox system) |
| Does a specific phosphorylation site on protein Y control contraction? | Point mutation knock-in (e.g., phospho-deficient or phospho-mimetic) |
| Does a disease-associated mutation in gene Z alter contractility? | Knock-in of the human mutation in mice or cells |
| Where and when is protein W expressed during contraction? | Tagged knock-in (e.g., GFP or HA tag) |
| Does overexpression of gene V enhance contraction? | Transgenic overexpression or viral delivery in smooth muscle |
| What is the role of a non-coding RNA in contraction? | CRISPR interference or activation library screening |
How to Study the vascular associated smooth muscle contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Wire myography | Force generation in isolated vessel segments | Assessing contractile responses to drugs or genetic manipulation |
| Calcium imaging | Intracellular Ca2+ concentration dynamics | Dissecting Ca2+ signaling in contraction |
| Western blotting | Phosphorylation of MLC20 and other proteins | Quantifying contractile pathway activation [3,5] |
| Co-immunoprecipitation | Protein-protein interactions | Studying adaptor protein complexes [5,8] |
| Computational modeling | Simulated contractile dynamics and stability | Predicting system behavior and identifying key parameters |
| RNA-seq | Transcriptomic changes in smooth muscle cells | Identifying genes regulated during contraction |
| CRISPR screening | Gene function in contraction at scale | Discovering novel regulators of vascular tone |
Functional Contraction Assays
Wire myography and pressure myography are standard methods to measure vascular smooth muscle contraction ex vivo. These techniques assess force generation and vessel diameter changes in response to agonists or genetic modifications [3,4].
Calcium Imaging and Signaling
Fluorescent Ca2+ indicators (e.g., Fura-2, Fluo-4) are used to measure intracellular Ca2+ dynamics in vascular smooth muscle cells during contraction. This helps dissect Ca2+-dependent and Ca2+-sensitization pathways.
Phosphorylation and Protein Interaction Assays
Western blotting with phospho-specific antibodies detects MLC20 phosphorylation and Rho-kinase activity. Co-immunoprecipitation and proximity ligation assays reveal protein interactions, such as paxillin-Rho-kinase binding [5,8].
Computational Modeling
Mathematical and computational models simulate vascular smooth muscle cell contraction to predict dynamics and identify instabilities. These models integrate biochemical and mechanical parameters and can guide experimental design.
How CRISPR Can Be Used to Study GO:0014829 vascular associated smooth muscle contraction
Knockout
CRISPR knockout of candidate genes (e.g., RhoA, ROCK, MLCK) in vascular smooth muscle cells or mouse models can determine their necessity for contraction. Smooth muscle-specific Cre-lox knockout avoids developmental lethality and allows adult studies.
Point Mutation
Knock-in of point mutations (e.g., phospho-deficient or phospho-mimetic residues) in genes like MYL9 or PPP1R12A can dissect the role of specific phosphorylation sites in contraction. This approach provides mechanistic insights beyond simple knockout.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) or human disease-associated mutations into endogenous loci enables real-time visualization and functional studies of contractile proteins in their native context.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of genes such as YY1 or RhoA can test sufficiency in enhancing contraction. This is useful for validating gain-of-function mechanisms in vascular disease.
How EDITGENE Supports vascular associated smooth muscle contraction Research
Researchers studying vascular associated smooth muscle contraction-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation in vascular smooth muscle cell models, from knockout to point mutation and overexpression, accelerating mechanistic discovery and therapeutic target validation.
Contact EDITGENE today to design your custom CRISPR model for vascular associated smooth muscle contraction research.
Frequently Asked Questions About vascular associated smooth muscle contraction
What is GO:0014829?
GO:0014829 is the Gene Ontology term for vascular associated smooth muscle contraction, a biological process where actin/myosin complex activity generates force through ATP hydrolysis, changing smooth muscle geometry and regulating vascular tone.
What genes are involved in vascular associated smooth muscle contraction?
Key genes include MYLK, MYL9, RHOA, ROCK1, ROCK2, PPP1R12A, CALM1, ACTA2, and adaptor proteins like BCAR1 (CAS) and PXN [3,5,8].
How does calcium trigger vascular smooth muscle contraction?
Calcium binds calmodulin, activating MLCK, which phosphorylates MLC20 to initiate actomyosin cross-bridge cycling and force generation.
What is the role of Rho-kinase in vascular smooth muscle contraction?
Rho-kinase inhibits myosin light chain phosphatase, increasing MLC20 phosphorylation and Ca2+ sensitization, thereby enhancing contraction [3,5].
How is vascular smooth muscle contraction studied experimentally?
Common methods include wire myography, calcium imaging, Western blotting for phospho-MLC20, and computational modeling [1,3].
What diseases are linked to abnormal vascular smooth muscle contraction?
Hypertension, vasospasm, sickle cell disease vasculopathy, and age-related vascular dysfunction are associated with dysregulated contraction [2,4,7].
Can CRISPR be used to study vascular smooth muscle contraction?
Yes, CRISPR knockout, point mutation knock-in, and overexpression models in vascular smooth muscle cells enable precise functional studies of contractile genes [3,5].
What is the role of YY1 in vascular smooth muscle contraction?
YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.
How does sphingosylphosphorylcholine (SPC) affect vascular smooth muscle?
SPC induces abnormal contraction via endocytosis-dependent uptake and activation of Rho-kinase, with paxillin playing a key role [5,6].
What are the challenges in modeling vascular smooth muscle contraction?
Computational models reveal inherent instabilities, and the system is highly nonlinear, requiring integrated experimental and theoretical approaches.
Conclusion
Vascular associated smooth muscle contraction (GO:0014829) is a fundamental biological process that regulates vascular tone and blood pressure through the coordinated activity of actin, myosin, and a complex signaling network involving calcium, Rho-kinase, and cytoskeletal adaptor proteins [3,5,8]. Dysregulation of this process underlies major cardiovascular diseases, including hypertension, vasospasm, and sickle cell vasculopathy [2,4,7]. Recent advances in epigenetic regulation, such as YY1-mediated m6A modification, and computational modeling have expanded our understanding of this process [1,2]. CRISPR-based genetic models are powerful tools to dissect the causal roles of specific genes and mutations, and EDITGENE offers comprehensive services to support such research, from knockout to knock-in and library screening, accelerating the discovery of novel therapeutic targets for vascular diseases.
References
- 1. Giudici A et al.. 2024. Instability in Computational Models of Vascular Smooth Muscle Cell Contraction.. Ann Biomed Eng 52(9):2403-2416 PMID: 38949730
- 2. Ye W et al.. 2025. YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.. Cardiovasc Res 121(12):1898-1916 PMID: 40795179
- 3. Liu Z et al.. 2018. Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.. Biochem Pharmacol 153:91-122 PMID: 29452094
- 4. Azubuike-Osu S et al.. 2020. Mechanisms of enhanced vascular smooth muscle contraction induced by sickle erythrocyte constituents.. Niger J Physiol Sci 35(1):26-32 PMID: 33084615
- 5. Zhang Y et al.. 2024. Paxillin participates in the sphingosylphosphorylcholine-induced abnormal contraction of vascular smooth muscle by regulating Rho-kinase activation.. Cell Commun Signal 22(1):58 PMID: 38254202
- 6. Tsurudome N et al.. 2023. Sphingosylphosphorylcholine (SPC), a Causative Factor of SPC-Induced Vascular Smooth Muscle Cells Contraction, Is Taken Up via Endocytosis.. Cells 12(2) PMID: 36672200
- 7. Yildiz O. 2007. Vascular smooth muscle and endothelial functions in aging.. Ann N Y Acad Sci 1100:353-60 PMID: 17460198
- 8. Tang DD et al.. 2003. Role of Crk-associated substrate in the regulation of vascular smooth muscle contraction.. Hypertension 42(4):858-63 PMID: 12885796
